Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma

Воропаева, Е. Н.; Поспелова, Т И; Воевода, М. И.; Maksimov, V. N.; Orlov, Yuriy L.; Серегина, О. Б.

doi:10.1186/s12920-019-0484-9

Cited by 30 publications

(22 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We were able to identify 22% of DLBCL patients harboring TP53 mutations, similar to previous studies. 11,12,33 Additionally, 89% of TP53 mutations were located in exons 5-8 in DBD and showed no statistically significant difference for DBD versus non-DBD mutations in relationship to poor prognosis, as previously reported. 23,34,35 Both TP53 mutation and accumulation of wild-type p53 led to readings of IHC-determined overexpression.…”

Section: Discussionsupporting

confidence: 74%

Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients

Qin¹,

Jiang²,

Liu³

et al. 2020

CMAR

View full text Add to dashboard Cite

Background/Aim TP53 mutation is recognized as a negative prognostic factor for patients with diffuse large B-cell lymphoma (DLBCL). Here, we present the characteristics of TP53 mut DLBCL patients following investigation of the effect of a treatment approach on survival of TP53 mut DLBCL patients. Methods A total of 44 DLBCL patients with TP53 mut and treated with an R-CHOP regimen were included for analysis. Patients who failed to achieve a complete response (CR) to initial treatment or relapsed in the first 6 months after initial CR were deemed to have primary refractory disease. Results Among 44 patients harboring TP53 mutations who underwent upfront R-CHOP or R-CHOP–like treatment, 21 (47.7%) had limited-stage and 23 (52.3%) presented advanced-stage disease. Apart from the seven patients receiving upfront surgical resection, 37 had measurable disease under the R-CHOP regimen, with 59.1% (n=26) developing primary refractory disease. Seven limited-stage patients after early complete resection and one with residue resection remained event-free at median follow-up of 37 months. Multivariate analysis revealed that elevated baseline lactate dehydrogenase (LDH), extranodal involvement (two or more), Ann Arbor stage, and locoregional treatment (surgery or radiation therapy) were independent indicators for progression-free survival (PFS). After adjustment for baseline LDH and extranodal involvement, adding locoregional treatment including surgery and radiation to the R-CHOP regimen significantly improved PFS ( p =0.008) and overall survival ( p =0.017) in limited-stage TP53 mut DLBCL patients compared to R-CHOP–only treatment. Conclusion This study presents the characteristics of TP53 -mutated DLBCL and implies a potential benefit of locoregional treatment in limited-stage DLBCL patients with TP53 mutations.

show abstract

Section: Discussionsupporting

confidence: 74%

Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients

Qin¹,

Jiang²,

Liu³

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…Overall, this issue includes reports of recent medical genomics applications in cancer and databases development, as well as case reports, continuing series on BMC Med Genomics special post-conference journal issues [10,17,22,23]. We hope for continuing international exchange and education via the schools and competitions for young scientists.…”

mentioning

confidence: 99%

“…The BGRS\SB-2018 conference highlights were published in 2018 [ 5 – 7 ], and continued the BMC Medical Genomics special issues in 2019 [ 8 ]. Public discussion of the conference presentations at the open access platforms of BioMed Central and other publishers serve as an international educational resource for young scientists [ 9 , 10 ].…”

mentioning

confidence: 99%

Medical genomics at the Systems Biology and Bioinformatics (SBB-2019) school

et al. 2020

Self Cite

View full text Add to dashboard Cite

Next-Generation Sequencing-driven analysis and Systems Biology approaches commonly serve as a backdrop for a study of a tumor genome. This issue of BMC Medical Genomics SBB-2019 ("Systems Biology and Bioinformatics") presents recent works discussed at the 11th Young Scientists School "Systems Biology and Bioinformatics"-2019, held in Novosibirsk, Russia (http://conf.bionet.nsc.ru/sbb2 019/en/). Here we collated some cancer gene expression studies, some mutation profiling studies as well as some insightful case reports. The SBB school series on bioinformatics proceeds annually since 2008 under the joint steerage of the Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences and Novosibirsk State University [1, 2]. We had publications in special topic issues after the Schools before in BMC Genomics, BMC Medical Genomics and related BioMed Central family journals since 2014 [3-5]. The SBB Schools in Novosibirsk were initially conceived as satellite event for young scientists held at the same time as BGRS\SB (Bioinformatics of Genome Regulation and Structure \ Systems Biology) conference series, since 1998 taking place biannually. The recent BGRS\SB-2020 event in Novosibirsk was over at the time of the current journal issue publication (https://bgrssb.icgbio.ru/2020/). Other special issues (Supplements) to the BMC journals in the fields of genomics, genetics, bioinformatics, and medical genetics are published at BMC Genomics, BMC Genetics and three other BMC journals. The BGRS\SB-2018 conference highlights were published in 2018 [5-7], and continued the BMC Medical

show abstract

“…Bioinformatics analysis of omics data allows identifying molecular genetic changes associated with the disease development, as well as markers of prognosis and response to therapy. Alterations in DNA methylation and histone modification profiles widely occur in malignant tumors [ 15 ], [ 16 ]. In this study, Kobelyatskaya and co-authors analyzed changes in DNA methylation in three groups of prostate cancer patients.…”

mentioning

confidence: 99%